Commentary: Over the next few years, drug manufacturers will release a host of new drugs that are more complex and, in many cases, more effective than weve had access to in the past. There will be better solutions for common problems, and new solutions for uncommon ones. Specialty drugs, many of them precision therapies, will offer tremendous promise for better health outcomes across the breadth of human health and treatment.
Not surprisingly, most of these drugs will have breathtaking price tags, often a high multiple of conventional drugs. Specialty drugs are an exploding growth industry, with spending rising
The Hepatitis C drug, Sovaldi, made
Also see:
But in most cases there is no evidence that drug pricing is connected to hard business costs or patient value. Prices often seem capricious, making it difficult for purchasers to understand the relationship between additional cost and new impact. For example, U.S. cost for a new cholesterol management drug, referred to at this point only as PCSK9, is expected to be
The magnitude of the potential cumulative cost is staggering.
Then there is the dramatic difference often 300% to 1,000% between the pricing here and in other developed nations, where we can assume that drug sales also are profitable. Gilenya, a multiple sclerosis drug, can cost almost
Also see:
Despite widespread knowledge of health care excesses and premiums that have grown at a multiple of general inflation for more than a decade, business has doggedly continued to participate in health care coverage. Its entirely reasonable, then, for drug companies to believe that organizational purchasers are too pre-occupied with other matters to mobilize around a problem like specialty drug costs. Nor do employers and unions want to take a hard line. After all, what benefits manager wants to tell an employee that the company wont pay for a new medicine that could improve her childs life?
Questions to ask
Purchasers might ask a couple questions. First, what additional measurable value does a new drug offer? This is hardly cynical.
Second, what is pricing tethered to? What cost components, exactly, are used to develop U.S. pricing, to make the drugs so much more expensive here than in other countries?
The possibility of specialty drug pricing financially overwhelming business and union health plans is real. Purchasers will be alarmed to find that their drug costs are growing much faster than other, already exorbitant health care spending. CFOs and benefits managers will watch their specialty drug spending, and calculate. To their minds, excessive specialty drug costs could capsize their plans, making it untenable to maintain good health coverage without compromising some other important health plan benefit. Just as worrisome, these costs will substantially increase their already heavy health care burdens, eating into the bottom line.
Also see:
Because most every business and union offering coverage will be affected, specialty drugs could become the issue that finally mobilizes organizational purchasers against the broader problem of health care profiteering. Businesses are coming together, collaborating with common purpose, trying to learn more, searching for ways to manage specialty drug costs, and finding themselves frustrated by their lack of meaningful options. Thats a prescription for a mobilized response.
In their zeal for even greater profits, specialty drug manufacturers could finally lay on the straw that breaks the tolerance of the nations health care purchasers for excessive health costs. If that happens, almost certainly, health care will finally change.
Brian Klepper is a health care analyst and commentator based in Atlantic Beach, Florida.